Research programme: mood disorder and neurological disorder therapeutics - Phenoquest

Drug Profile

Research programme: mood disorder and neurological disorder therapeutics - Phenoquest

Alternative Names: AF-08 mAb; AFC-08

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Affectis Pharmaceuticals
  • Class Monoclonal antibodies
  • Mechanism of Action Dinoprostone receptor antagonists; Purinergic P2 receptor antagonists; TMEFF2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Major depressive disorder

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Major depressive disorder in Germany
  • 22 Oct 2015 Preclinical development is ongoing in Germany
  • 22 Oct 2015 AFC 08 licensed to Phenoquest (Affectis' pipeline, October 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top